A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Delafloxacin (Primary) ; Delafloxacin (Primary) ; Linezolid; Moxifloxacin; Moxifloxacin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms DEFINE-CABP
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 15 Dec 2016 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
    • 15 Dec 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018.
    • 15 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top